Answers are grounded in this paper and cite their sources.
Pediatric obesity and youth-onset type 2 diabetes (T2D) are increasingly prevalent chronic diseases linked to high cardiometabolic morbidity and long-term cardiovascular risks. To complement lifestyle changes, glucagon-like peptide-1 receptor agonists (GLP-1RAs)—such as liraglutide and semaglutide—have emerged as powerful tools for pediatric weight and glycemic management. Clinical evidence confirms that these agents drive significant weight loss in adolescents, and liraglutide is effective in children as young as six. Furthermore, GLP-1RAs improve glycemic control in youth with T2D through glucose-dependent insulin and glucagon regulation, delayed gastric emptying, and central appetite modulation. Safe clinical integration requires precise patient selection, gradual dose titration, and behavioral support. Clinicians must screen for strict precautions like medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and pregnancy. Continuous monitoring is essential to track gastrointestinal side effects, gallbladder disease, nutritional adequacy, growth, pubertal development, and psychological well-being. Beyond direct clinical care, significant hurdles remain regarding equitable access, insurance coverage, treatment persistence, and psychosocial factors. While current evidence supports their implementation, critical knowledge gaps persist regarding optimal treatment duration, comparative effectiveness, and the role of emerging incretin-based therapies. The chronic administration of these agents in pediatric obesity and type 2 diabetes mandates rigorous longitudinal surveillance of their effects on reproductive health, next-generation outcomes, and prolonged off-target safety.
No takes yet. Share an insight, caveat, or question.
Jacob et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: